Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GRI Bio, Inc.VLON · Entity 8336 | Director | May 14, 2021 | May 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GRI Bio, Inc.
Report date May 14, 2021 · Filed May 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2031-05-14 | Direct | 15,000 |
Reported balance
After 2021-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-14 · Grant · Acquired 15,000 · Balance 15,000 F1: The stock option vests as to 50% of the underlying shares of common stock on June 30, 2021, then in two equal installments on September 30, 2021 and December 31, 2021, such that the stock option fully vests on December 31, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2031-05-14 | Direct | 30,000 |
Reported balance
After 2021-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-14 · Grant · Acquired 30,000 · Balance 30,000 F2: The stock option vests in 24 equal monthly installments such that the stock option is fully vested on the second annual anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 50% of the underlying shares of common stock on June 30, 2021, then in two equal installments on September 30, 2021 and December 31, 2021, such that the stock option fully vests on December 31, 2021.
F2: The stock option vests in 24 equal monthly installments such that the stock option is fully vested on the second annual anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2021 Filed May 18, 2021 20:08 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001104659-21-068837 · tm2116776-5_4.xml · derivative · entry 2 Levi Ofir · CIK 0001843598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-14 F2 · derivative.exercise_date: The stock option vests in 24 equal monthly installments such that the stock option is fully vested on the second annual anniversary of the date of grant. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:08 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001104659-21-068837 · tm2116776-5_4.xml · derivative · entry 1 Levi Ofir · CIK 0001843598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares of common stock on June 30, 2021, then in two equal installments on September 30, 2021 and December 31, 2021, such that the stock option fully vests on December 31, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.